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ARTICLE
High-throughput screen reveals sRNAs regulating
crRNA biogenesis by targeting CRISPR leader to
repress Rho termination
Ping Lin 1,2, Qinqin Pu2, Qun Wu 2,3, Chuanmin Zhou2, Biao Wang2, Jacob Schettler 2, Zhihan Wang 2,
Shugang Qin2, Pan Gao 2, Rongpeng Li4, Guoping Li5, Zhenyu Cheng 6, Lefu Lan 7, Jianxin Jiang1 &
Min Wu 2
Discovery of CRISPR-Cas systems is one of paramount importance in the field of micro-
biology. Currently, how CRISPR-Cas systems are finely regulated remains to be defined. Here
we use small regulatory RNA (sRNA) library to screen sRNAs targeting type I-F CRISPR-Cas
system through proximity ligation by T4 RNA ligase and find 34 sRNAs linking to CRISPR loci.
Among 34 sRNAs for potential regulators of CRISPR, sRNA pant463 and PhrS enhance
CRISPR loci transcription, while pant391 represses their transcription. We identify PhrS as a
regulator of CRISPR-Cas by binding CRISPR leaders to suppress Rho-dependent transcription
termination. PhrS-mediated anti-termination facilitates CRISPR locus transcription to gen-
erate CRISPR RNA (crRNA) and subsequently promotes CRISPR-Cas adaptive immunity
against bacteriophage invasion. Furthermore, this also exists in type I-C/-E CRISPR-Cas,
suggesting general regulatory mechanisms in bacteria kingdom. Our findings identify sRNAs
as important regulators of CRISPR-Cas, extending roles of sRNAs in controlling bacterial
physiology by promoting CRISPR-Cas adaptation priming.
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CRISPR-Cas systems endow prokaryotes with adaptive andheritable immunity1–3, which employ RNA-guidednucleases for recognizing and destroying invading DNA or
RNA4–6. CRISPR-Cas systems function through three phases:
spacer acquisition, expression of CRISPR RNA (crRNA), and
interference2,7. At the spacer acquisition stage, foreign nucleic acids
from an invader would be incorporated into CRISPR loci as new
spacers, forming expanded archives of past infections. Following the
spacer acquisition is the crRNA biogenesis phase, in which CRISPR
loci are transcribed to yield precursor crRNA (pre-crRNA) and are
then cleaved by Cas proteins into mature crRNAs. In the inter-
ference and final phase, crRNA-guided Cas proteins cleave foreign
DNA or RNA and mediate their degradation. Although extensive
biological and ecological studies have built a framework about
the structures and functions of the CRISPR-Cas system1,8,9, we have
just begun to understand the fascinating prokaryote immunity10.
Importantly, the CRISPR leader sequence exhibits the specificity to
constitute an ideal target substrate for spacer integration during the
adaptation phase11, but little is known regarding whether the leader
is critical for producing pre-crRNA transcripts during the crRNA
biogenesis phase.
Regulatory RNAs are an essential group of molecules that
facilitate various aspects in gene expression, such as transcription,
RNA processing or stabilization, and translation12,13. Small reg-
ulatory RNAs (sRNAs), the primary group of regulatory RNA in
bacteria (50- to 400 bp), are a major regulator of numerous
metabolic and stress responses in bacteria14–16. In particular,
prompt responses to various stimuli are shown to be controlled
by sRNAs17,18. However, it is unknown whether sRNAs can
modulate CRISPR-Cas adaptive immunity by influencing the
transcriptional activity.
Prokaryotes use Rho-dependent termination mechanisms for
RNA polymerase (RNAP) recycling in most species of bacteria
kingdom19. Rho along with its cofactor NusG bind to the tran-
scription terminator pause sites that function as an attenuator20,21.
Rho moves along the nascent RNA molecules that enable it to
function at RNA polymerase, resulting in the dissociation of RNA
polymerase complex and termination of transcription.
Here, we used a combination of approaches to search for
candidate sRNAs that may regulate CRISPR-Cas function. Based
on the data from GRIL-Seq (global small non-coding RNA target
identification by ligation/sequencing)22, the studies derived from
genome-wide identification of sRNA in Pseudomonas
aeruginosa23,24 and our initial analyses, we constructed high-
throughput library encoding 274 sRNAs to ligate to the CRISPR
leader via T4 RNA ligase-catalyzed linking assay. The screened
candidate sRNAs that target CRISPR leaders were characterized
by functional assays and potential binding domains in the targets
were predicted using the IntaRNA computing tool and assessed
by biochemical assays. PhrS is shown with the most significant
interference with Rho-mediated termination by interacting with
Type I-F CRISPR leaders, resulting in transcriptional activation of
CRISPR loci and then stimulation of CRISPR-Cas adaptive
immunity against bacteriophage invasion. As PhrS also shows the
similar functions in type I-C/-E CRISPR-Cas systems, demon-
strating pervasiveness of sRNA-mediated control of CRISPR-Cas
activities. Our data reveal the function of CRISPR leaders, which
not only contain a conserved integration host factor to create the
ideal target substrate for Cas1-Cas2 to spacer acquisition11,25,26,
but also facilitates crRNA biogenesis by controlling CRISPR loci
transcription.
Results
sRNA library screening identifies regulators of CRISPR loci.
T4 RNA ligase 1 (single-stranded RNA ligase 1) links two base-
paired RNA molecules by catalyzing ATP-dependent formation
of a 3ʹ→5ʹ phosphodiester bond on single-stranded RNAs, which
offers a means for investigating the interaction of bacterial sRNAs
and RNA molecules in vivo22. We used T4 RNA ligase 1 to
generate sRNA-RNA chimaera to selectively probe the inter-
actome for interactions between bacterial sRNAs and CRISPR-
Cas system (Fig. 1a). We investigated the effect of T4 RNA ligase
1 expression on P. aeruginosa PA14 strain throughout the growth
period (Fig. 1b), which showed a decline in viability for 1 h after
IPTG treatment. Therefore, the inducible expression of T4 RNA
ligase 1 was maintained up to 1 h for each experiment.
The P. aeruginosa PA14 I-F CRISPR-Cas comprises Cas1,
Cas3, Csy1–4 complex flanked by two CRISPR loci (Supplemen-
tary Fig. 1a). To identify potential sRNAs that target leaders in
CRISPR loci, we used the pKH6 vector22 to create an arabinose-
inducible vector (pKH6-CRISPR1 leader and pKH6-CRISPR2
leader) and introduced the vector into PA14 containing pKH-
t4rnl1, respectively. After IPTG and arabinose treatment, we used
a library of 274 P. aeruginosa endogenous sRNAs to detect the
ligated chimeric sRNA-CRISPR leader using sRNA-specific
primers and CRISPR leader-specific primers as described in
Fig. 1a. We observed 9 and 25 sRNA-CRISPR leader chimeras for
CRISPR1 and CRISPR2 leaders, respectively (Fig. 1c, d,
Supplementary Fig. 1b, and Supplementary data 1). Computa-
tional analysis using the online IntaRNA tool also predicts
interaction between CRISPR loci and sRNAs (Fig. 1e). The
difference between Fig. 1d, e is possibly due to the linking
between CRISPR leader and sRNAs through 5ʹ monophosphates
to 3ʹ hydroxyl groups by T4 RNA ligase 1, but the majority of
P. aeruginosa sRNA molecules are transcript products containing
5ʹ triphosphoryl termini. In order to investigate and characterize
whether any of these 34 sRNAs interact with and/or regulate
CRISPR loci, we constructed each of the sRNA over-expressing
plasmids in combination with CRISPR1-lacZ or CRISPR2-lacZ
fusion plasmid, and transformed them into PA14 to monitor lacZ
activity. Of the 35 sRNAs tested, one sRNA pant391 repressed
CRISPR2-lacZ expression by more than twofold, while sRNAs
pant463 and PhrS increased CRISPR2-lacZ expression (Fig. 1f).
Of note, PhrS had the strongest positive effect on the level of
CRISPR locus, which was further investigated (Fig. 1f).
To detect specific ligation of candidate targets of PhrS with
CRISPR loci, we performed reverse transcription-polymerase
chain reaction (RT-PCR) to analyze the ligated products as
described in Fig. 1a using phrS-specific primer and CRISPR locus-
specific primer, followed by induction expression of RNA for up
to 20 min in the presence of T4 RNA ligase or an inactive T4
RNA ligase (t4K99N). We noticed that the amplicons of PhrS-
CRISPR2 leader chimeras were induced to facilitate the expres-
sion of PhrS for up to 20 min, but abrogated by an inactive T4
RNA ligase (Fig. 1g). Sequencing analysis of the amplicons
confirms that the junction sequences are the PhrS-CRISPR2
leader chimeras (Fig. 1h). These data indicate that PhrS is a
candidate sRNA that interacts with type I-F CRISPR leaders of
PA14 strain.
PhrS promotes CRISPR2 locus transcription and interference.
To investigate the influence of PhrS on CRISPR-Cas functionality,
we evaluated the expression pattern of cas operon or CRISPR loci
in the PA14 phrS deletion strain (ΔphrS) vs. the wild-type (WT)
strain. Only CRISPR2 locus, not cas operon and CRISPR1 locus,
exhibited lower expression in PA14 ΔphrS than WT throughout
the survey growth period, but restored expression levels close to
the WT upon complementing PA14 ΔphrS (Fig. 2a). We then
measured the transformation efficiency of CRISPR-Cas on elim-
inating CRISPR-targeted plasmids that contained protospacers in
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CRISPR1 (denoted CR1-sp1) or CRISPR2 (denoted CR2-sp1) in
PA14 ΔphrS (Supplementary Fig. 1a). Strikingly, mutation of phrS
had no effect on CRISPR1-dependent CRISPR interference
(Fig. 2b, left), but resulted in equal transformation frequencies of
PA14 ΔTCR lacking cas genes when CRISPR2-targeted DNA was
used (Fig. 2b, right), reflecting a lack of CRISPR2 interference and
immunity functionality that is regulated by PhrS. We also
observed that CRISPR-sensitive phage JBD25, which targets a
spacer in CRISPR1 locus, failed to replicate in PA14 WT, ΔphrS
and ΔphrS/p-phrS (Fig. 2c and Supplementary Fig. 1a). Con-
versely, CRISPR-sensitive JBD18, which targets a spacer in
CRISPR2 locus, was able to replicate in PA14 ΔphrS, but failed to
replicate in WT and ΔphrS/p-phrS (Fig. 2c). Taken together, our
data demonstrate that PhrS modulates efficiency of CRISPR2
interference, hence controlling its functionality.
Based on these findings, we reasoned that transcriptional
changes of CRISPR2 locus may be associated with PhrS. Northern
blot analysis supported this premise—that PhrS is required for
the synthesis of crRNA in CRISPR2 locus (Fig. 2d). Moreover,
addition of CRISPR2 locus into PA14 ΔphrS showed sufficient
efficiency to account for the CRISPR interference and immunity
(Fig. 2e, f), implying that CRISPR2 locus was indeed activated by
sRNA PhrS. Meanwhile, expression of CRISPR2 locus in PA14
ΔphrS background strain resulted in lowered plaques efficiency of
JBD18 (Fig. 2g), corresponding with less potent production of
crRNA of CRISPR2 locus in PA14 ΔphrS.
Altogether, our results demonstrate that PhrS stimulates
CRISPR-Cas-dependent immunity and enhances host defense
against invasive element correction by production of the potent
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Fig. 1 T4 RNA ligase-catalyzed ligation of sRNAs to P. aeruginosa CRISPR loci. a Schematic of the formation of sRNAs chimeras with CRISPR leader by T4
RNA ligase. Two RNA molecules were linked to form pKH6-CRISPR leader plasmid for expressing CRISPR leader and pKH13-t4rhl1 for expressing T4 RNA
ligase. Also shown is reverse transcription-polymerase chain reaction (RT-PCR)-based strategy for determining chimeras of CRISPR leader with sRNA.
b T4 RNA ligase or its inactive mutation in t4rnl1 gene with lysine (K) to asparagine (N) affects P. aeruginosa cell growth. c Screening of 274 P. aeruginosa
sRNAs library (239 intergenic sRNAs candidate and 35 annotated sRNAs) linking to CRISPR leader by T4 RNA ligase. Pink represents sRNA-containing
chimeras; green represents non-target sRNA chimeras. d Detection of chimeras of P. aeruginosa 35 annotated sRNAs linking to CRISPR leader sequences by
T4 RNA ligase in vivo, relative to Supplementary Fig. 1b. Pink represents sRNA-containing chimeras; green represents non-target sRNA chimeras.
e IntaRNA prediction of P. aeruginosa annotated sRNAs interactions with CRISPR leader. f Overexpression sRNA to screen candidate sRNAs on regulation
of CRISPR1-lacZ and CRISPR2-lacZ fusion. g Amplicons were detected for PhrS-CRISPR2 leader chimeras. Primer for targets PhrS with CRISPR leader (as
shown in a) was carried out for PCR step. PCR production for PhrS and housekeeping gene (pheS) was carried out to ensure the genes expression in all
samples. h Sequencing reads corresponding to PhrS chimeras with CRISPR2 leader by TA-clone sequencing. Results are shown with mean ± SEM from
three independent experiments. **P < 0.01, *P < 0.05, one-way ANOVA plus Tukey test
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creg motif of PhrS is required for regulating CRISPR system.
In addition to its regulatory function, PhrS has an open reading
frames (ORF) that encodes a conserved 37 amino acid peptide
(Supplementary Fig. 2a)27. We found that there is no difference of
CRISPR2 locus transcription between PA14 ΔphrS and
ΔphrS/phrS-ORF (restored expression of internal ORF of PhrS) by
lacZ reporter and northern blotting (Supplementary Fig. 2b, c)
and similarly no difference of CRISPR-Cas interference was
noticed (Supplementary Fig. 2d, e). These data demonstrated that
the internal ORF of PhrS-encoded protein had no effect on
CRISPR-Cas functionality, indicating that PhrS as a sRNA may
act on PA14 CRISPR-Cas adaptive immunity.
The secondary structures of PhrS were characterized to contain
a conserved region (creg element, 12 nt in length)28. To evaluate
which motif or region of PhrS is essential for CRISPR-Cas system,
we overexpressed three PhrS functional domain variants
(pJT-phrSΔcreg, pJT-phrScmut: point mutations introduced into
the conserved creg element, and pJT-phrScreg) in PA14 ΔphrS
background strain (Fig. 3a). As shown in Fig. 3b, pJT-phrScreg in
PA14 ΔphrS background, but not pJT-phrSΔcreg and pJT-phrScmut,
stimulated transcription levels of CRISPR2-lacZ fusion gene (as a
reporter) similar to that of pJT-phrS. In addition, northern
blotting showed that pJT-phrS or pJT-phrScreg does not cause
reduced expression of CRISPR2 locus compared to PA14 WT
(Fig. 3c). Furthermore, pJT-phrScreg showed more efficient
transformation inhibition in CRISPR-Cas interference, whereas
pJT-phrSΔcreg and pJT-phrScmut did not (Fig. 3d). We also found
that CRISPR-sensitive JBD18 can replicate on pJT-phrSΔcreg and
pJT-phrScmut, but not on pJT-phrScreg (Fig. 3e). Our observations
suggest that CRISPR2 regulation is dependent on the creg
element of PhrS.
As shown in Fig. 1a, we used T4 RNA ligase 1 to link two base-
paired RNA molecules. We hypothesized that PhrS acts as a
regulatory molecule by interacting directly with a leader sequence
to control CRISPR2 locus transcription. Computational analysis
by IntaRNA tool showed the potential interaction between PhrS,
a
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Fig. 2 PhrS stimulates CRISPR2 crRNA transcription and subsequent CRISPR-Cas interference. a cas-lacZ or CRISPR-lacZ activity in PA14 WT and ΔphrS
mutant backgrounds throughout the growth period. b Transformation efficiency with CR1-sp1 and CR2-sp1 plasmids in PA14 WT or ΔphrS mutant. c Phage
plaque assay of JBD18 and JBD25 for PA14 WT, ΔphrS, ΔphrS/p-phrS, and PA14 lacking a CRISPR-Cas system (ΔTCR). d Northern blot of crRNA levels,
PhrS, and 5S RNA in PA14 WT and its mutant strains. e Retention of the CRISPR-targeted plasmid CR2-sp1 in the PA14 ΔphrS background strain with
pgRNA-CRISPR2 that coexpressed the crRNA in the CRISPR2 locus. f Transformation efficiency of CR2-sp1 vector in PA14 ΔphrS background strain with
pgRNA-CRISPR2. g The same JBD18 phage was tested on PA14 ΔphrS background strain containing pgRNA empty vector or plasmid expression the
indicated CRISPR2. Results are shown with mean ± SEM from three independent experiments. **P < 0.01, *P < 0.05, one-way ANOVA plus Tukey test
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especially creg element in PhrS, and +491 to +502 segments of
CRISPR2 (Fig. 3f, upper), supporting the hypothesis that base-
pairing between PhrS and CRISPR2 leader is responsible for
PhrS-mediated CRISPR locus transcription. To test this idea, GFP
reporter containing three variants of CRISPR2 leader (Fig. 3f,
lower) were transformed into PA14 WT. Similar to ΔphrS
pleaderCRISPR2-GFP strain, GFP-containing strain plating analy-
sis demonstrated that mutant-binding sites in the CRISPR2 leader
displayed much weaker fluorescence (Fig. 3g). Moreover, western
blot analysis of GFP showed that three variants strains had
weaker GFP quantity than the WT pleaderCRISPR2-GFP strain
(Fig. 3h). These findings attest that the binding sites in the
CRISPR2 locus are highly subject to CRISPR2 locus transcrip-
tional regulation. Taken together, these findings demonstrate that
the precise binding sites between creg element of PhrS and
CRISPR2 leader is required for the transcription of CRISPR locus
to control CRISPR-Cas immunity response.
PhrS controls Rho-dependent termination at CRISPR2 locus.
We next sought to determine the mechanism how PhrS exerts its
function in CRISPR-Cas systems. PhrS as an activator of PqsR
synthesis stimulates PQS biosynthesis operon (PqsA-E)28. How-
ever, mutation of PqsA-E has no effect on CRISPR2 locus tran-
scription (Supplementary Fig. 3a, b) and consequent CRISPR-Cas
interference (Supplementary Fig. 3c, d), indicating that PhrS-
mediated PQS biosynthesis operon had no role in CRISPR-Cas
expression or function. As some sRNAs modulate gene function
through interaction with chromosomal DNAs14, the “reverse
transcription-associated trap (RAT)” assay29 was performed to
detect RNA/DNA interaction through pull-down and PCR by
interacting with DNA-specific primers (Supplementary Fig. 4a).
We observed no interaction between PhrS and CRISPR2 locus
chromosomal DNAs as well as cas1 locus and pheS locus (Sup-
plementary Fig. 4b).
sRNAs are shown to be powerful regulators because they can
modulate both transcription and translation14. Owing to only
pre-crRNA transcribed from CRISPR loci, we focused on PhrS
influence on the process of transcription (transcriptional elonga-
tion and termination) at CRISPR2 locus. We hypothesized that
PhrS may regulate CRISPR2 transcription via inhibition of Rho-
dependent transcriptional termination, because there is no G–C
rich hairpin loop at CRISPR2 leader for intrinsic termination
(Rho-independent termination) to control RNA transcription. To
investigate this, we first tested whether Rho terminates CRISPR2
transcription using one round transcription reaction method.
Transcription of CRISPR2 template (Supplementary Fig. 5a) gave
rise to an intact transcript without Rho (Supplementary Fig. 5b,
lane 1). However, Rho together with NusG prompted strong
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Fig. 3 creg motif of PhrS is essential for crRNA regulation of CRISPR-Cas adaptive immunity. a Diagram of the sRNA PhrS and mutations. creg motif is
marked with bold. Eleven nucleotides of creg were deleted in the plasmid pJT-phrSΔcreg. pJT-phrScmut plasmid contained site mutations in creg motif.
pJT-phrScreg represent regions with expression of creg motif. b LacZ activity as determined in the PA14 ΔphrS background strain harboring the PhrS
expression plasmid pJT-PhrS, plasmid pJT-PhrSΔcreg, plasmid pJT-phrScmut, or plasmid pJT-phrScreg with toluate (2 mM final concentration). c Northern blot
of CRISPR2 crRNA production in PA14 ΔphrS background strain containing the PhrS expression plasmid pJT-phrS, plasmid pJT-phrSΔcreg, plasmid
pJT-phrScmut, or plasmid pJT-phrScreg. d Transformation efficiency of CR2-sp1 vector in PA14 ΔphrS background strain within the plasmid pJT-phrS, pJT-
phrSΔcreg, pJT-phrScmut, or pJT-phrScreg. e Phage plaque of CRISPR-sensitive phage JBD18 on PA14 ΔphrS background harboring the plasmid pJT-phrS, pJT-
phrSΔcreg, pJT-phrScmut, or pJT-phrScreg. f IntaRNA (Freiburg RNA tools) prediction of PhrS interactions with CRISPR2 leader target (upper). A diagram of
leader binding site with phrS knockout or mutant with red parts mark (lower). g GFP fluorescence in PA14 strains or ΔphrS transformed with
pleaderCRISPR2-GFP, pleaderCRISPR2-Δ-GFP, pleaderCRISPR2-mut1-GFP, or pleaderCRISPR2-mut2-GFP plasmid, respectively. GFP mode is on the left and the
visible light of light mode is on the right). hWestern blot analysis of GFP in the PA14 WT or ΔphrS transformed with pleaderCRISPR2-GFP, pleaderCRISPR2-Δ-
GFP, pleaderCRISPR2-mut1-GFP, or pleaderCRISPR2-mut2-GFP plasmid, 5 μg total proteins were used to western blotting analysis. Results are shown with
mean ± SEM from three independent experiments. **P < 0.01, *P < 0.05, one-way ANOVA plus Tukey test
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was abolished by brief exposure to Rho inhibitor bicyclomycin
(BCM)30 (Supplementary Fig. 5b, lane 3). A GFP reporter with or
without the CRISPR2 leader was generated for in vivo experiment
(Supplementary Fig. 5c). In comparison with PA14 WT contain-
ing pGFP, plating PA14 WT with pleaderCRISPR2-GFP demon-
strated significantly subdued fluorescence (Supplementary
Fig. 5d), whereas fluorescence of pleaderCRISPR2-GFP strain
recovered to the control level in the presence of BCM
(Supplementary Fig. 5e). Further, quantitative PCR (qPCR)
quantification of gfp shows that pleaderCRISPR2-GFP strain
exhibited a stronger response to BCM than the pGFP control
(Supplementary Fig. 5f, g). In summary, these findings reveal
CRISPR2 leader encompassing a Rho-dependent termination
signal.
To test whether PhrS influences Rho function on CRISPR2
leader, GFP fluorescence assay in PA14 WT and ΔphrS contain-
ing pleaderCRISPR2-GFP plasmid was utilized (Fig. 4a). PA14 WT
and ΔphrS containing GFP reporter cultured in luria broth (LB)
medium displayed the same growth rate (Fig. 4b, left). None-
theless, the expression level of GFP gradually increased in PA14
WT rather than the ΔphrS mutant strain throughout the surveyed
growth period (Fig. 4b, right). Considering the Rho activity on
CRISPR2 leaders, our data indicate PhrS represses Rho-
dependent termination, leading to increased GFP levels. Plating
PA14 ΔphrS transformed with pleaderCRISPR2-GFP plasmid
displayed markedly reduced fluorescence compared to that of
WT (Fig. 4c). Supplementing BCM increased the fluorescence of
PA14 ΔphrS (Fig. 4d). Moreover, GFP levels in PA14 WT were
altered slightly, while PA14 ΔphrS manifested almost a 100-fold
augmentation with BCM treatment confirmed by transcript and
protein determination (Fig. 4e, f). This was consistent with the
expression of crRNA molecules in the CRISPR2 locus by
northern blotting (Fig. 4g). In addition, the plaquing efficiency
of phage JBD18 was reduced compared to PA14 ΔphrS with BCM
treatment (Fig. 4h). Collectively, these observations support our
notion that PhrS inhibits Rho-dependent transcriptional termi-
nation to stimulate CRISPR2 crRNA synthesis against phage
infection.
To further verify this concept, overexpression of PhrS resulted
in the robust increase of lacZ transcripts, consistent with the
response to BCM (Supplementary Fig. 6a, b). Remarkably, BCM
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Fig. 4 PhrS inhibits Rho-dependent termination with leader region within CRISPR2 locus. a Diagram of pleaderCRISPR2-GFP construct that includes leader
region of CRISPR2 locus. “P” represents Ptac promoter. TSS represents transcription start site. RBS represents a ribosome-binding site. The fragment of
qPCR is marked as green. b Time-course of GFP levels in PA14 strains (WT and ΔphrS) transformed with pleaderCRISPR2-GFP grew in LB medium. Bacteria
density (left) and GFP levels (right) were simultaneously monitored. c GFP fluorescence of PA14 WT and ΔphrS harboring pleaderCRISPR2-GFP reporter.
d GFP fluorescence of PA14 WT and ΔphrS harboring pleaderCRISPR2-GFP cultured on LB with agar containing 8 μg/ml bicyclomycin (BCM). e Ratio of gfp
in PA14 WT or ΔphrS harboring pleaderCRISPR2-GFP without or within BCM. fWestern blot of GFP in PA14WT and ΔphrS transformed with pleaderCRISPR2-
GFP, 5 μg total proteins were used to western blotting analysis. g Northern blot of crRNA levels in PA14 WT and ΔphrS with or without BCM. 5S probe,
loading control. h Tenfold dilution of lysates of CRISPR-sensitive phages JBD18 and JBD25 grew on bacterial lawns of PA14 WT and ΔphrS without or within
BCM. i RNA immunoprecipitation (RIP) was performed to test PhrS affecting Rho loading with leader sequence via His-Rho. Box plots: center line
represents median, min to max (whiskers) and individual data points (blue). j RNA pull-down to investigate PhrS-mediated inhibition of Rho loading with
leader region by detection of Rho proteins through western blotting. Bands corresponding to His-Rho were observed in leader RNA pull-down with PhrS in a
dose-dependent manner. Results are shown with mean ± SEM from three independent experiments. **P < 0.01, *P < 0.05, one-way ANOVA plus Tukey test
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leader in response to PhrS increase (Supplementary Fig. 6c).
Altogether, PhrS-mediated repression of Rho in CRISPR2 leader
is attributed to the stimulatory effect of PhrS on CRISPR2
transcription.
Rho has to bind RNA to achieve termination21. To investigate
the mechanism by which PhrS causes the inhibition of Rho, we
performed crosslinked RNA immunoprecipitation (RIP) via His-
Rho protein to investigate whether PhrS affects Rho loading or
translocation with the CRISPR2 leader. We detected the gradually
decreased enrichment of the CRISPR2 leader with increasing
doses of PhrS (Fig. 4i), indicating that PhrS affects Rho loading.
Consequently, to confirm PhrS-mediated inhibition of the
biochemical interaction of the CRISPR2 leader with Rho, we
performed RNA pull-down assays. The biotin-labeled CRISPR2
leader was transcribed, hybridized to PhrS, and added His-Rho
protein for incubation. Samples captured on streptavidin
magnetic beads were detected through western blotting analysis
to identify and confirm that Rho binding gradually reduced due
to the increased PhrS (Fig. 4j). Altogether, PhrS represses Rho
loading to stimulate CRISPR2 transcription.
Reconstitution of PhrS on anti-termination in CRISPR2 locus.
In vitro reconstituted system enabling a single round transcrip-
tion assay showed that PhrS, similar to BCM treatment, abolished
Rho-mediated robust termination (Fig. 5a), meaning that PhrS
interacts directly with CRISPR2 leader to inhibit Rho-dependent
termination.
Next, we estimated the activity for Rho-mediated termination
and PhrS-mediated anti-termination at the CRISPR2 locus. qRT-
PCR was performed to determine various regions (UTR [untrans-
lated region], 5ʹORF and ORF) of CRISPR2-lacZ transcript in
PA14 WT and ΔphrS strains containing translational CRISPR2-
lacZ reporter (Fig. 5b). Normalized to “ORF” with each strain, we
attained the determination of the termination efficiency within
lacZ between PA14 WT and ΔphrS. Compared to BCM
treatment, the [UTR]/[ORF] or [5ʹUTR]/[ORF] value in PA14
WT without BCM was increased due to powerful Rho-mediated
termination (Fig. 5c). Furthermore, a higher value of [UTR]/
[ORF] or [5ʹUTR]/[ORF] in PA14 ΔphrS compared to WT
inhibited the efficient Rho-dependent termination (Fig. 5c),
consistent with a stronger termination phenotype within the
CRISPR2 leader in PA14 ΔphrS strain. Indeed, treatment of BCM
drastically reduced the values of [UTR]/[ORF] or [5ʹUTR]/[ORF]
in PA14 WT and ΔphrS (Fig. 5c). To further probe the underlying
mechanism, we also detected the native CRISPR2 transcript (pre-
crRNA) in PA14 Δcsy4 and Δcys4/ΔphrS strains given Csy4 being
responsible for pre-crRNA processing into short crRNAs in
PA1431. To this end, we found that PA14 Δcsy4 displayed greatly
increased expression levels of pre-crRNAs in Δcsy4 strains
deficient in PhrS (Fig. 5d). [UTR]/[ORF] and [5ʹUTR]/[ORF]
ratio of the transcript of the CRISPR2 locus for PA14 Δcys4/
ΔphrS strain significantly exceeded PA14 Δcsy4, as well as BCM
treatment (Fig. 5e). Taken together, these data support the
cumulative effect of PhrS on Rho anti-termination as determined
in vitro.
Direct target of PhrS and CRISPR2 inhibits Rho termination.
sRNAs regulate diverse processes through a variety of distinct
mechanisms14. The precise base-paired sites between the creg
element of PhrS and the CRISPR2 leader are required for the
CRISPR2 locus transcription (Fig. 3). We hypothesized that PhrS
acts as a regulatory molecule by interacting directly with a leader
sequence to control Rho-dependent in CRISPR2 locus. To test
this notion, we evaluated whether a specific region of the
CRISPR2 leader is required, plating PA14 WT was transformed
with pleaderCRISPR2(+x+y)-GFP derivatives with various seg-
ments of the CRISPR2 leader (Supplementary Fig. 7a). All strains
had equal growth rates (Supplementary Fig. 7b, c, lower), but
WT pleaderCRISPR2(+400+600)-GFP exhibited much diminished
fluorescence, as well as WT pleaderCRISPR2-GFP intensity,
compared to other derivative strains (Supplementary Fig. 7b, c,
upper), indicating that Rho termination activity may be attri-
butable to a ~+ 400 to +600 segment of the CRISPR2 leader,
which overlap the binding sites between PhrS and the CRISPR2
leader.
Next, to further test whether the binding sites are required for
PhrS-mediated anti-termination in a CRISPR locus, we further
generated three variants of the CRISPR2 leader (Figs. 3f and 6a)
to perform transcription analysis. We found that anti-termination
mediated by PhrS was specific for the binding sites in the
CRISPR2 locus, because PhrS has no effect on Rho-dependent
termination for other three variants of a CRISPR2 leader region
without PhrS-binding sites (Fig. 6a, left). Moreover, Rho together
with NusG leaded to obvious transcription termination (Fig. 6a,
right, lane 2), which was not suppressed by PhrS with deficiency
of PhrS-binding sites in the transcriptional template (Fig. 6a,
right, lane 3), but was greatly inhibited by BCM (Fig. 6a, right,
lane 4). Furthermore, GFP-containing strain plating analysis also
illustrated that the mutant-binding sites of the CRISPR2 leader
displayed remarkably attenuated fluorescence (Fig. 6b, upper).
Supplementing BCM increased the fluorescence of three variants
strains (Fig. 6b, lower). Moreover, qPCR analysis of gfp revealed
that three variants strains exhibited significantly lower GFP
quantity than the WT pleaderCRISPR2-GFP strain (Fig. 6c),
consistent with the intensity of the GFP signal (Fig. 6d). GFP
expression in the three variants was highly induced after BCM
treatment (Fig. 6c, d), indicating that the binding sites of PhrS
and CRISPR2 locus are highly subject to the activity of PhrS-
mediated anti-termination.
To further substantiate this conclusion, GFP assay was used
with PA14 strains: WT, ΔphrS, ΔphrS/pJT-phrScmut carrying
points mutations introduced into the creg element and ΔphrS/
pJT-phrScmut/p-phrS, which harbored pleaderCRISPR2-GFP repor-
ter plasmid. Of note, GFP-containing strain plating analysis also
demonstrated that mutant creg sites of PhrS in ΔphrS/pJT-
phrScmut strain, similar to ΔphrS strain, displayed greatly
weakened fluorescence, but restored to the control level of the
WT upon complementing ΔphrS/pJT-phrScmut strain (Fig. 6e,
upper). Supplementing BCM increased the fluorescence of ΔphrS/
pJT-phrScmut strain (Fig. 6e, lower). Moreover, qRT-PCR-based
quantification and western blot analysis of GFP showed that
ΔphrS/pJT-phrScmut strain had much weaker GFP quantity than
the WT strain (Fig. 6f, g). Altogether, we conclude that the
inhibition of Rho termination is dependent on PhrS direct
binding to CRISPR2 leader, resulting in elevated expression of the
CRISPR locus in the PA14 I-F CRISPR-Cas system.
PhrS on anti-termination is a common event for CRISPR
system. To further characterize the role of sRNA PhrS in multiple
types CRISPR-Cas regulation, we tested two other types I-C/-E
CRISPR-Cas systems, each with at least one CRISPR array, which
P. aeruginosa ST277 and SM4386 possess PhrS or its homologs
with PA14 strains (Supplementary Fig. 8a). We observed that cas
operon expression, same to CRISPR2 (I-E) and CRISPR1 (I-F)
was not altered by PhrS (Supplementary Fig. 8b). Remarkably,
CRISPR1 locus-associated type I-C and I-E systems, similar to
CRISPR2 (I-F), exhibited significant reduction in PhrS-deficient
strains (Supplementary Fig. 8b). In agreement, complementation
of PhrS with plasmids restored the expression of CRISPR1 (I-C),
CRISPR1 (I-E), and CRISPR2 (I-F).
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Next, we examined whether PhrS-mediated anti-termination
occurs at CRISPR loci in multiple CRISPR-Cas systems. IntaRNA
platform analysis showed that these CRISPR loci also possess a
potential target site for the creg element of PhrS (Fig. 7a).
Monitoring the β-galactosidase activities confirmed that all these
CRISPR loci were downregulated in PhrS-deficient strains vs. WT
strains (Fig. 7b). Pre-treatment of PhrS-deficient strains with
BCM led to an apparent increase of three CRISPR loci (Fig. 7b).
Importantly, overexpression of PhrS resulted in upregulation of
three CRISPR loci (Fig. 7c). The findings confirm PhrS-mediated
anti-termination for type I-C/-E/-F CRISPR loci. Collectively,
these observations illustrate that PhrS blocks Rho-dependent
termination by targeting CRISPR leaders, which is likely a
common phenomenon in multiple CRISPR-Cas systems among
the bacteria kingdom (Fig. 7d).
Discussion
CRISPR-Cas systems are discovered throughout diverse microbes,
empowering these microorganisms with unique mechanisms for
adaptive immunity3. Through a high-throughput approach, we
identified sRNA PhrS as a regulator of CRISPR-Cas functionality
to stimulate CRISPR loci transcription. sRNAs possess an
impressive effect on bacterial behaviors through a variety of
mechanisms, such as changes in RNA conformation12,18. Here,
we elaborate that PhrS inhibits Rho-dependent termination to
ensure CRISPR transcription, establishing a sophisticated prin-
ciple of sRNA-mediated transcription control of CRISPR-Cas
adaptive immunity. Furthermore, the formation of PhrS-leader
complex impedes Rho loading on RNA molecules in the CRISPR
loci. Our results illuminate a concept that CRISPR leaders not
only contain a conserved integration host factor to create the ideal
target substrate for Cas1-Cas2 during spacer acquisition11,25,26,
but also facilitate crRNA biogenesis via control of CRISPR loci
transcription.
Co-evolutionary dynamics between bacteria and phage presses
the emergence of bacterial defense systems32. Understanding
CRISPR-Cas adaptive immune systems in bacteria has improved
our knowledge of bacterial biology and phage–host interaction.
While insight into the CRISPR-Cas spacer acquisition and
interference stage has expeditiously amassed, the molecular
machineries for promptly and precisely stimulating CRISPR-Cas
adaptive immunity is rather limited. Previous studies show that
bacteria control CRISPR-Cas systems through quorum sensing
autoinducers33,34. We reveal that PhrS activates the transcription
of pre-crRNA in CRISPR-Cas systems. In agreement, PhrS
deletion reduces CRISPR-Cas immunity against phage and
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Fig. 5 Reconstituted PhrS-mediated anti-termination acts on CRISPR2 locus. a PhrS sRNA inhibits Rho termination at leader sequence of CRISPR2 locus
in vitro. Preformed elongation was transcribed without (lane 1 and 5) or with (lane 2–4) Rho and NusG. The Rho-dependent termination was estimated
without (lane 2) or with PhrS sRNA (lane 3) or BCM (lane 4). The bracket represents termination regions (T). b Diagram of CRISPR leader with lacZ ORF
and CRISPR array. The fragments for qRT-PCR are labeled as green. The dynamic value of [UTR]/[ORF] was used to assess termination efficiency of Rho-
dependent termination by PhrS in CRISPR leader, normalized by CRISPR array and lacZ RNA. Increased value represents more termination efficiency, but a
lower value indicates reduction of termination efficiency. c Transcript expression of various lacZ zones quantified for PA14 WT or ΔphrS before and after
BCM treatment. d Levels of CRISPR array measured for the PA14 Δcsy4 and Δcsy4/ΔphrS mutant. e Transcript expression of various CRISPR locus zones
quantified for PA14 Δcsy4 or Δcsy4/ΔphrS before and after BCM treatment. Results are shown with mean ± SEM from three independent experiments.
**P < 0.01, *P < 0.05, one-way ANOVA plus Tukey test
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PhrS. PhrS stimulates PqsR synthesis to facilitate synthesis of
quinolone signal, which links to oxygen availability to impact the
formation of P. aeruginosa biofilms28. Our findings define a
regulatory role of sRNA PhrS in CRISPR-Cas activity to battle
against phage infection, demonstrating an added layer of reg-
ulation in CRISPR-Cas adaptive immunity.
The general termination factor Rho plays an important role in
riboswitch-mediated gene regulation that alters the expression of
associated protein-coding regions35,36. Recently, it was shown
that long 5ʹUTRs of bacterial genes powerfully facilitate Rho-
mediated regulatory signals15. Here, we provide strong evidence
that Rho-dependent transcription termination acts at CRISPR
leaders, demonstrating that Rho is required for the control of
bacterial non-coding RNA transcription. This phenomenon is
also seen in type I-C/-E CRISPR-Cas systems, indicating that
CRISPR leader perhaps functions as a general target site for
Rho-mediated regulation. Importantly, our findings reveal a
surprisingly widespread mechanism in which PhrS mediates anti-
termination of transcription by inhibiting the activity of Rho-
dependent transcription termination via base-pairing with the
regulatory motifs of CRISPR loci leader, which affects the tran-
scription of CRISPR loci. The default repressive state of Rho
activity can be partially relieved with the alterations of nutrient or
metabolic conditions. For example, Rho is active within several
well-characterized E. coli riboswitch, such as thiM, which
responds to intracellular levels of TPP35,37. Our data suggest that
the formation of a PhrS-leader complex can inhibit Rho-
dependent termination rather than stimulate it. Furthermore,
our research leads us to believe that PhrS disrupts Rho loading
along with the nascent CRISPR leader or 5ʹUTR to control
transcriptional process in P. aeruginosa.
The environmental cues, for instance cell density, may stimu-
late sRNA expression to modulate bacterial behavior via the base-
pairing mechanism16,38. Increasing numbers of sRNAs have been
characterized, which has significantly improved understanding of
their biological function. The regions for base-pairing between
sRNA and RNA molecules are marked as seed region. Interest-
ingly, there is only one seed region in some sRNAs, such as
RybB39, whereas numerous seed regions for others matching
various RNA molecules, such as Spot 4240. The precise
mechanism of the creg element of PhrS directly targeted with the
CRISPR2 leader is required for CRISPR locus transcription,
revealing that the seed regions for specific base-pairing lead to the
unwinding of structural elements and ultimately repression of the
premature transcription termination in a CRISPR locus.
In summary, our work discovers a mechanism of sRNA-
mediated control of CRISPR-Cas systems, showing that PhrS
finely regulates anti-termination elements to activate the tran-
scription of CRISPR loci that functions throughout bacterial
CRISPR-Cas adaptive immunity in response to phage infection.
There are now five major classes of sRNAs in bacteria18. Con-
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Fig. 6 The effect of PhrS sRNA on CRISPR transcription via a direct regulatory target. a Transcription reaction shows that PhrS did not hamper Rho
termination on CRISPR2 leader mutants’ template with or without BCM. b GFP fluorescence in PA14 strains containing pleaderCRISPR-GFP, pleaderCRISPR-Δ-
GFP, pleaderCRISPR-mut1-GFP, or pleaderCRISPR-mut2-GFP plasmid, respectively, without (upper) or with (lower) BCM. c qPCR for GFP levels with or without
BCM for PA14 strains containing pleaderCRISPR-GFP, pleaderCRISPR-Δ-GFP, pleaderCRISPR-mut1-GFP, or pleaderCRISPR-mut2-GFP plasmid, respectively.
d CRISPR2 leader mutation affect GFP intensity. e GFP fluorescence in PA14 WT, ΔphrS, ΔphrS/pJT-phrScmut, and ΔphrS/pJT-phrScmut/p-phrS strains
transformed with pleaderCRISPR-GFP plasmid without (upper) or with (lower) BCM. f qPCR assay for GFP levels without or with BCM for PA14 WT, ΔphrS,
ΔphrS/pJT-phrScmut, and ΔphrS/pJT-phrScmut/p-phrS strains transformed with pleaderCRISPR-GFP plasmid. g Western blot analysis of GFP in the PA14 WT,
ΔphrS, ΔphrS/pJT-phrScmut, and ΔphrS/pJT-phrScmut/p-phrS strains transformed with pleaderCRISPR-GFP plasmid. Ten micrograms total proteins were used
in western blotting analysis. Results are shown with mean ± SEM from three independent experiments. **P < 0.01, *P < 0.05, one-way ANOVA plus
Tukey test
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understanding of their biological action in bacteria, but whether
or not other classes of sRNAs or global sRNAs play a pivotal role
in regulating CRISPR-Cas systems, especially controlling cas
operon expression, remains unfolded. In addition, our study
reveals sRNA-mediated control of CRISPR-Cas system via
RNA–RNA interaction, indicating that other RNA modifications
at CRISPR loci, such as epigenetic modifications (M5C or M6A),
might also play a part in the transcriptional or post transcrip-
tional control of CRISPR-Cas systems, warranting further
investigation.
Methods
Bacteria and plasmids. Bacterial strains (Supplementary data 2) are derivatives of
P. aeruginosa PA14, ST277 and SM4386 strains. We used E. coli DH5a or P.
aeruginosa strains to construct the plasmids (Supplementary data 2). E. coli DH5a
or P. aeruginosa strains were cultured in LB or LB with agar containing ampicillin
(100 μg/ml, Fisher Scientific), chloramphenicol (12.5 μg/ml, Sigma), tetracycline
(10 μg/ml, Sigma), kanamycin (100 μg/ml, Fisher Scientific), carbenicillin (100 μg/
ml, Fisher Scientific), gentamicin (75 μg/ml, ACROS) or bicyclomycin (BCM) (8
μg/ml, Santa Cruz).
Library screen for sRNA chimeras by qPCR. We used a pKH6 vector from
Dr. Stephen Lory of Harvard Medical School22 to construct pKH6-CRISPR2 and
pKH6-CRISPR1 plasmid. These plasmids were each transfected into PA14 con-
taining pKH-t4rnl1, respectively. Overnight cultures of PA14 WT with pKH13-
t4rnl1 (or pKH13-t4K99N) and pKH6-CRISPR2 (or pKH6-CRISPR1) plasmid
were grown in LB broth with antibiotic and diluted the overnight culture to
OD600= 0.01. When OD600= 0.5, IPTG was added for 1 h incubation and then
added the L-arabinose to 20% for different time points. The cells were centrifuged
at 12,000 rpm/min for RNA isolation with DNase treatment. One microgram of
total RNA was converted to complementary DNA (cDNA) was synthesized with
SuperScript III First-Strand Synthesis system (Invitrogen). RT-PCR were per-
formed using GoTaq Green Master Mix (Promega) with specific primers
(Supplementary data 3). The PCR products were recovered and cloned into a
pMD-19 vector (Takara) for sequencing.
Plasmid retention and transformation of efficiency assay. The plasmid CR1-
sp1 and CR2-sp1 were used to perform plasmid retention and transformation of
efficiency assay in PA14-WT and its derived mutation strains according to
Hoyland-Kroghsbo33,41. For plasmid retention assay, PA14-WT and its derived
mutants were electroporated with plasmid CR1-sp1 or CR2-sp1 and cultured in LB.
Colony forming units (CFU) were calculated on luria broth with agar containing
antibiotic to calculate the percentage of plasmid retention. For transformation of
efficiency assay, strains transfected with 1 μg CR1-sp1 and CR2-sp1 plasmid were
shaken for 1 h at 37 °C and plated on lysogeny broth medium with antibiotic
overnight. CFUs were quantified and transformation of efficiency was calculated as
the percentage colonies transformed by CR1-sp1 and CR2-sp1 compared with
untargeted plasmid.
Phage isolation and plaque assay. Phages were isolated from lysogen (Supple-
mentary data 2) according to Marino42. Plaque assay on bacterial lawns of PA14
WT or derivatives strains was conducted at 37 °C on LB agar (1.5%) plates with a
lower percentage of LBTop agar (0.3%). Added 1 х 108 bacteria cells to 4 ml LBTop
agar and transformed to LB agar plate as an even layer. The plates were spotted
with 3.5 μl of each phage lysate on the lawn and grown overnight. The observed
circular zones of clearing indicate the lysis of the tester strains.
β-Galactosidase assay. P. aeruginosa containing lacZ reporters (Supplementary
data 2) were grown for β-galactosidase assay for type I-C/-E/-F CRISPR-Cas system
according to Joshua P. Ramsay43. Briefly, all integrative lacZ reporter strains were
electroporated and grown in LB with tetracycline at 30 °C to detect β-galactosidase
assay according to Adrian G. Patterson34. The relative fluorescence intensity was
monitored using Bio-TeK Synergy HT Multi-Mode Microplate Reader (Bio-Tek,
Winooski, VT). The plate-reader software calculated Vmax to normalize the value of
RFU/s/OD600.
Protein reporter assays. Measuring GFP fluorescence: P. aeruginosa PA14 con-
taining GFP reporter were cultured on LB with agar for 20 h, which was imaged at
GFP fluorescence mode by IVIS XRII system (PerkinElmer, Waltham, MA).
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Fig. 7 PhrS-mediated anti-termination in CRISPR loci of multiple types CRISPR-Cas systems is a general phenomenon. a IntaRNA (Freiburg RNA tools)
prediction of PhrS sRNA interaction with 5ʹUTR of CRISPR locus in multiple types CRISPR-Cas system. b CRISPR-lacZ activity for multiple types CRISPR-Cas
system in WT or ΔphrS strain with or without BCM. c CRISPR-lacZ activity for multiple types CRISPR-Cas system in WT without PhrS overexpression, after
PhrS overexpression. d Proposed model of PhrS-mediated regulation of CRISPR-Cas adaptive immunity. Bacterial small RNA PhrS inhibits the Rho-
dependent termination to promote the expression of CRISPR loci, expanding function of sRNA in activating CRISPR-Cas adaptive immunity. Results are
shown with mean ± SEM from three independent experiments. **P < 0.01, *P < 0.05, one-way ANOVA plus Tukey test
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GFP assay in the liquid culture for measure GFP intensity: corresponding strains
containing the reporters were cultured to OD600= 1.0 and diluted 20-fold to
measure GFP in SPECTRAmas GEMINI-XS Spectrofluorometer (Molecular
Devices, San Jose, CA).
RNA isolation and qPCR. RNA purification with DNAase I digestion was per-
formed by the Direct-zolTM RNA MiniPrep kit (ZYMO RESEARCH, Irvine, CA).
cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit
(ThermoFisher Scientific, Waltham, MA). qPCR was analyzed by Maxima SYBR
Green qPCR Master Mix (ThermoFisher Scientific, Waltham, MA) with gene-
specific primers (Supplementary table 1).
Northern blot analysis. Five microgram of total RNA was separated by 6% TBE-
urea polyacrylamide gels in 1x TBE and then transferred to Hybond-XL mem-
branes (GE-Healthcare, Pittsburgh, PA). Using ultraviolet to cross-linking and
hybridizing with gamma32P-ATP labeled oligonucleotide probes (Supplementary
table 1). After washing three times to remove unwanted probe, the bands were
detected.
sRNA PhrS synthesis. PhrS templates with T7 promoter sequence (Supplemen-
tary table 2) were amplified by RT-PCR. PhrS sRNA was transcribed with
MEGAscript T7 kit according to manufacturer’s protocols with TURBO DNase
treatment.
In vitro transcription. For transcription reaction, the procedure was previously
described by Sedlyarova et al.15 with modification. Briefly, the initial elongation
complex was formed with 75 nM of corresponding transcription templates (Sup-
plementary Table 2) and 100 nM RNA polymerase (RNAP) holoenzyme in 100 μl
of 40 mM Tris-HCl pH= 8.0; 20 mMMgCl2; 50 mM NaCl; 0.003% IGEPAL; 5 mM
β-mercaptoethanol with 2 μl RNase inhibitor (Takara Bio USA, Mountain View,
CA). Transcription reaction mix (25 μM GTP, UTP, ATP-P-32) was performed at
22 °C for 5 min incubation and then mixed with 1 μM Rho with NusG proteins
with or without the PhrS sRNA or bicyclomycin. Heat the mixture containing
1 mM ATP and 100 μM other NTPs to transcribe at 37 °C with 10 min and stop the
reaction with 1x TBE, 8M Urea, 20 mM EDTA, 0.025% xylencyanol, 0.025%
bromophenol blue at 95 °C. The samples were separated by 6% TBE-urea
polyacrylamide gels.
Western blotting. The samples derived from PA14 WT and its derived mutation
strains were separated and transferred to nitrocellulose membranes (GE-Health-
care, Pittsburgh, PA). Membranes were incubated with mouse monoclonal anti-
body against GFP (Biolegend, San Diego, CA) and His-tag (ThermoFisher
Scientific, Waltham, MA) at 1:5000 for overnight at 4 °C with primary
antibodies44,45. After washing, adding corresponding secondary antibodies for
1.5 h. After washing five times with washing buffer, the protein bands were
visualized by chemiluminescence.
RNA immunoprecipitation (RIP). Anti-His antibody was used for RIP assay. One
microgram of His-Rho were used to pull down the RNA of CRISPR leader incu-
bated with different concentration of PhrS. The reactants were washed three times
with RIPA buffer (150 mM NaCl, 50 mM Tris, 0.5% sodium deoxycholate, 0.1%
SDS, 1% NP-40 with RNase inhibitor [Takara Bio USA, Mountain View, CA]) and
then washed twice with another washing buffer (1 M NaCl, 50 mM Tris, 0.5%
sodium deoxycholate, 0.1% SDS, 1% NP-40). RNA isolation was used Direct-zolTM
RNA MiniPrep kit (ZYMO RESEARCH, Irvine, CA).
Biotinylated RNA pull-down. We used the Biotin RNA labeling mix (Sigma) and
T7 RNA polymerase to get the Biotin-CRISPR leader transcripts. Biotin-CRISPR
leader incubated with different concentration of PhrS were adsorbed onto strep-
tavidin magnetic beads and added His-Rho protein to incubation at 4 °C for 6 h.
After washing five times in RIP buffer (150 mM KCl, 25 mM Tris-HCl (pH 7.4),
0.5 mM DTT. 0.5% NP-40, and protease inhibitors), the eluted samples were
detected by western blot.
Statistical analysis. Values were obtained from three independent experiments,
shown as mean ± SEM. P-values were derived with GraphPad (GraphPad Software,
LaJolla, CA) using one-way analysis of variance (ANOVA) plus Tukey test.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Authors confirm that all data and materials in the study can be obtained from the
corresponding author (M.W.) upon reasonable request.
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